Published in Biochemistry on February 28, 1995
Neutron diffraction studies of Escherichia coli dihydrofolate reductase complexed with methotrexate. Proc Natl Acad Sci U S A (2006) 1.70
Millisecond timescale fluctuations in dihydrofolate reductase are exquisitely sensitive to the bound ligands. Proc Natl Acad Sci U S A (2010) 1.53
In pursuit of virtual lead optimization: the role of the receptor structure and ensembles in accurate docking. Proteins (2008) 1.01
Hydride transfer during catalysis by dihydrofolate reductase from Thermotoga maritima. Biochem J (2003) 1.01
In pursuit of virtual lead optimization: pruning ensembles of receptor structures for increased efficiency and accuracy during docking. Proteins (2009) 0.98
Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania. J Comput Aided Mol Des (1998) 0.95
Role of water in the catalytic cycle of E. coli dihydrofolate reductase. Protein Sci (2002) 0.91
Toward resolving the catalytic mechanism of dihydrofolate reductase using neutron and ultrahigh-resolution X-ray crystallography. Proc Natl Acad Sci U S A (2014) 0.87
Keep on moving: discovering and perturbing the conformational dynamics of enzymes. Acc Chem Res (2014) 0.85
Effects of fluorine substitution on the structure and dynamics of complexes of dihydrofolate reductase (Escherichia coli). Biophys J (1997) 0.81
Structure in an extreme environment: NMR at high salt. Protein Sci (2007) 0.81
Identification and energetic ranking of possible docking sites for pterin on dihydrofolate reductase. J Comput Aided Mol Des (1998) 0.76
Preliminary joint X-ray and neutron protein crystallographic studies of ecDHFR complexed with folate and NADP+. Acta Crystallogr F Struct Biol Commun (2014) 0.76
Site specific polarization transfer from a hyperpolarized ligand of dihydrofolate reductase. J Biomol NMR (2016) 0.75
Structures of ternary complexes of rat DNA polymerase beta, a DNA template-primer, and ddCTP. Science (1994) 5.57
Loop and subdomain movements in the mechanism of Escherichia coli dihydrofolate reductase: crystallographic evidence. Biochemistry (1997) 5.46
Serine proteases: structure and mechanism of catalysis. Annu Rev Biochem (1977) 5.37
Crystal structure of a complex between electron transfer partners, cytochrome c peroxidase and cytochrome c. Science (1992) 4.82
Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry (1997) 4.55
Crystal structure of T7 gene 4 ring helicase indicates a mechanism for sequential hydrolysis of nucleotides. Cell (2000) 4.27
Crystal structure of rat DNA polymerase beta: evidence for a common polymerase mechanism. Science (1994) 4.11
Structure of subtilisin BPN' at 2.5 angström resolution. Nature (1969) 3.98
Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. J Biol Chem (1982) 3.84
A type VII myosin encoded by the mouse deafness gene shaker-1. Nature (1995) 3.71
An open and closed case for all polymerases. Structure (1999) 3.26
The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. J Biol Chem (1985) 2.95
Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate. Science (1977) 2.88
Crystal structure of yeast cytochrome c peroxidase refined at 1.7-A resolution. J Biol Chem (1984) 2.56
Low-resolution electron-density and anomalous-scattering-density maps of Chromatium high-potential iron protein. J Mol Biol (1968) 2.46
Crystal structure of avian dihydrofolate reductase containing phenyltriazine and NADPH. J Biol Chem (1982) 2.45
The stereochemistry of peroxidase catalysis. J Biol Chem (1980) 2.35
Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes. Cell Calcium (2000) 2.32
Crystal structures of human DNA polymerase beta complexed with DNA: implications for catalytic mechanism, processivity, and fidelity. Biochemistry (1996) 2.25
Chymotrypsinogen: 2.5-angstrom crystal structure, comparison with alpha-chymotrypsin, and implications for zymogen activation. Biochemistry (1970) 2.23
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Subtilisin; a stereochemical mechanism involving transition-state stabilization. Biochemistry (1972) 2.13
Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun (1997) 1.96
Dihydrofolate reductase from Lactobacillus casei. X-ray structure of the enzyme methotrexate.NADPH complex. J Biol Chem (1978) 1.94
The crystal structure of a heptameric archaeal Sm protein: Implications for the eukaryotic snRNP core. Proc Natl Acad Sci U S A (2001) 1.94
A comparison of Fe 4 S 4 clusters in high-potential iron protein and in ferredoxin. Proc Natl Acad Sci U S A (1972) 1.93
Choice-making treatment of young children's severe behavior problems. J Appl Behav Anal (1996) 1.93
Directed mutagenesis of dihydrofolate reductase. Science (1983) 1.88
Crystal structure of unliganded Escherichia coli dihydrofolate reductase. Ligand-induced conformational changes and cooperativity in binding. Biochemistry (1991) 1.86
Enzyme-DNA interactions required for efficient nucleotide incorporation and discrimination in human DNA polymerase beta. J Biol Chem (1996) 1.85
X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (Novo). A model for the catalytic transition state. J Biol Chem (1975) 1.82
The structure of oxidized cytochrome c 2 of Rhodospirillum rubrum. J Biol Chem (1973) 1.73
Crystal structures of Escherichia coli dihydrofolate reductase: the NADP+ holoenzyme and the folate.NADP+ ternary complex. Substrate binding and a model for the transition state. Biochemistry (1990) 1.71
Functional role of aspartic acid-27 in dihydrofolate reductase revealed by mutagenesis. Science (1986) 1.68
Crystal structures of recombinant human dihydrofolate reductase complexed with folate and 5-deazafolate. Biochemistry (1990) 1.66
Iron transport in Mycobacterium smegmatis: ferrimycobactin reductase (nad(p)h:ferrimycobactin oxidoreductase), the enzyme releasing iron from its carrier. FEBS Lett (1975) 1.63
Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J Biol Chem (1985) 1.62
Siderophore presence in sputa of cystic fibrosis patients. Infect Immun (1991) 1.61
Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis. J Biol Chem (1982) 1.61
Orbital rhabdomyosarcoma. An analysis of 62 cases. Am J Ophthalmol (1966) 1.60
A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology (1995) 1.56
Two-Angstrom crystal structure of oxidized Chromatium high potential iron protein. J Biol Chem (1974) 1.55
An assessment of attitudes to, and extent of, the practice of denture marking in South Australia. Aust Dent J (1998) 1.52
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Development and validation of a Bayesian model for perioperative cardiac risk assessment in a cohort of 1,081 vascular surgical candidates. J Am Coll Cardiol (1996) 1.45
A structural basis for metal ion mutagenicity and nucleotide selectivity in human DNA polymerase beta. Biochemistry (1996) 1.45
A hypothetical model of the cytochrome c peroxidase . cytochrome c electron transfer complex. J Biol Chem (1980) 1.44
An x-ray crystallographic study of the binding of peptide chloromethyl ketone inhibitors to subtilisin BPN'. Biochemistry (1972) 1.44
The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant (2009) 1.44
Structure of dehydroquinate synthase reveals an active site capable of multistep catalysis. Nature (1998) 1.41
Preferred genetic evolutionary sequences in human breast cancer: a case study. Cytometry (1995) 1.40
A proposed model for interaction of polypeptides with RNA. Proc Natl Acad Sci U S A (1974) 1.39
Atomic coordinates for subtilisin BPN' (or Novo). Biochem Biophys Res Commun (1971) 1.37
Structural bases for function in cytochromes c. An interpretation of comparative x-ray and biochemical data. J Biol Chem (1973) 1.36
The crystal structure of cytochrome c peroxidase. J Biol Chem (1980) 1.35
Conservation of a CD1 multigene family in the guinea pig. J Immunol (1999) 1.34
The effects of meal schedule and quantity on problematic behavior. J Appl Behav Anal (1996) 1.32
Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation (1996) 1.31
Characterization of the metal ion binding helix-hairpin-helix motifs in human DNA polymerase beta by X-ray structural analysis. Biochemistry (1996) 1.30
Structure of the iron-sulfur cluster in the Chromatius iron protein at 2.25 Angstrom resolution. Cold Spring Harb Symp Quant Biol (1972) 1.30
Crystal structure of a novel trimethoprim-resistant dihydrofolate reductase specified in Escherichia coli by R-plasmid R67. Biochemistry (1986) 1.29
Impact of an intermediate care area on ICU utilization after cardiac surgery. Crit Care Med (1986) 1.29
"How much do you get paid if I volunteer?" Suggested institutional policy on reward, consent, and research. Hosp Health Serv Adm (1994) 1.26
Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine. Microb Comp Genomics (2000) 1.25
Polypeptide halomethyl ketones bind to serine proteases as analogs of the tetrahedral intermediate. X-ray crystallographic comparison of lysine- and phenylalanine-polypeptide chloromethyl ketone-inhibited subtilisin. J Biol Chem (1976) 1.25
Structural basis of non-specific lipid binding in maize lipid-transfer protein complexes revealed by high-resolution X-ray crystallography. J Mol Biol (2001) 1.24
Child pedestrian and bicyclist injuries: results of community surveillance and a case-control study. Inj Prev (1996) 1.24
Prognostic value of exercise thallium-201 imaging in patients presenting for evaluation of chest pain. J Am Coll Cardiol (1983) 1.22
Iron transport in Mycobacterium smegmatis: a restricted role for salicylic acid in the extracellular environment. Biochim Biophys Acta (1974) 1.21
An engineered disulfide bond in dihydrofolate reductase. Biochemistry (1987) 1.20
Determination by Raman spectroscopy of the pKa of N5 of dihydrofolate bound to dihydrofolate reductase: mechanistic implications. Biochemistry (1994) 1.18
Dihydrofolate reductase. The stereochemistry of inhibitor selectivity. J Biol Chem (1985) 1.17
Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study. Hepatology (1997) 1.16
Polymorphonuclear cell function in rheumatoid arthritis and in Felty's syndrome. Ann Rheum Dis (1981) 1.15
Histidine 52 is a critical residue for rapid formation of cytochrome c peroxidase compound I. Biochemistry (1993) 1.15
Re-examination of the charge relay system in subtilisin comparison with other serine proteases. J Biol Chem (1977) 1.14
The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther (2014) 1.14
Comparison of oxidation-reduction site geometries in oxidized and reduced Chromatium high potential iron protein and oxidized Peptococcus aerogenes ferredoxin. J Biol Chem (1974) 1.14
A hydrogen-bond network at the active site of subtilisin BPN'. Philos Trans R Soc Lond B Biol Sci (1970) 1.14
Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS). Clin Exp Immunol (2001) 1.12
Skeletal muscle and cardiovascular adaptations to exercise conditioning in older coronary patients. Circulation (1996) 1.11
IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol (1996) 1.11
X-ray structures of recombinant yeast cytochrome c peroxidase and three heme-cleft mutants prepared by site-directed mutagenesis. Biochemistry (1990) 1.10
The aromatic substrate binding site in subtilisin BPN' and its resemblance to chymotrypsin. Cold Spring Harb Symp Quant Biol (1972) 1.08
Yersinia pestis and plague. Biochem Soc Trans (2003) 1.06
Heme pocket interactions in cytochrome c peroxidase studied by site-directed mutagenesis and resonance Raman spectroscopy. Biochemistry (1988) 1.06
Anti-RANA antibody: a marker for seronegative and seropositive rheumatoid arthritis. Lancet (1980) 1.06
Purification and characterization of recombinant catalase-peroxidase, which confers isoniazid sensitivity in Mycobacterium tuberculosis. J Biol Chem (1997) 1.05
Compound I radical in site-directed mutants of cytochrome c peroxidase as probed by electron paramagnetic resonance and electron-nuclear double resonance. Biochemistry (1991) 1.05
Self-assembly in the carboxysome: a viral capsid-like protein shell in bacterial cells. Biochem Soc Trans (2007) 1.03
Differential expression of beta1 and beta2 integrins and L-selectin on CD4+ and CD8+ T lymphocytes in human blood: comparative analysis between isolated cells, whole blood samples and cryopreserved preparations. Clin Exp Immunol (2002) 1.02
Crystallographic structure refinement of Chromatium high potential iron protein at two Angstroms resolution. J Biol Chem (1975) 1.02
Tryptophan-191----phenylalanine, a proximal-side mutation in yeast cytochrome c peroxidase that strongly affects the kinetics of ferrocytochrome c oxidation. Biochemistry (1988) 1.02
Effect of arginine-48 replacement on the reaction between cytochrome c peroxidase and hydrogen peroxide. Biochemistry (1993) 1.02